| Date | Time | Source | Headline | Symbol | Company |
| 05/10/2011 | 8:00AM | PR Newswire (US) | JDRF and Amylin Partner to Investigate Co-Formulating Two Hormones for Treatment of Type 1 Diabetes | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 05/05/2011 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the Bank of America 2011 Healthcare Conference | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 05/05/2011 | 8:31AM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/27/2011 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/20/2011 | 5:15AM | Zacks | Amylin Loss In-Line with Estimates - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/18/2011 | 12:43PM | Zacks | Positive EU Opinion for Bydureon - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/18/2011 | 8:29AM | Dow Jones News | Amylin Pharma 1Q Loss Narrows On Cost-Cutting; Results Miss Views | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/18/2011 | 7:59AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/18/2011 | 7:30AM | PR Newswire (US) | Amylin Pharmaceuticals Reports First Quarter Financial Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2011 | 11:32AM | Dow Jones News | UPDATE: Lilly, Amylin, Alkermes Diabetes Drug Gets EU Backing | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2011 | 10:23AM | Dow Jones News | Amylin: Treatment For Metabolic Disorder Shows Promise | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2011 | 9:00AM | PR Newswire (US) | Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2011 | 8:02AM | Dow Jones News | Lilly, Amylin, Alkermes Diabetes Drug Moves Ahead In EU | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2011 | 7:25AM | Business Wire | Bydureon™ Recommended for Approval in Europe | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/13/2011 | 9:03AM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/13/2011 | 9:00AM | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/11/2011 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Webcast First Quarter Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/11/2011 | 12:27PM | Dow Jones News | EARNINGS PREVIEW: US Drug Makers' 1Q To Benefit From Higher Prices | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/08/2011 | 1:59PM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/06/2011 | 4:37PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/06/2011 | 4:37PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/06/2011 | 4:37PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/06/2011 | 3:18PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 4:39PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 4:39PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 4:38PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 7:35AM | Marketwired | Healthcare Acquisition Activity on the Rise as Key Patents Run Out | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/16/2011 | 8:00AM | PR Newswire (US) | Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/14/2011 | 10:04AM | PR Newswire (US) | Zacks Analyst Blog Highlights: Amylin Pharmaceuticals, Eli Lilly and Company, Alkermes, Novo Nordisk and The Dow Chemical | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/10/2011 | 10:20AM | PR Newswire (US) | Exenatide Once Monthly Showed Positive Results in Phase 2 Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |